GK is independent director of Hilleman Laboratories and vice chair of the board for CEPI. JPF and GK are members of the WHO Strategic Advisory Group of Experts in Immunization Working Group on COVID-19 vaccines. MG participates in one of eight SARS-CoV-2 vaccine development projects supported by the Scientific and Technological Research Council of Turkey since March, 2020. MEB and PH are developers of a COVID-19 vaccine construct, which was licensed by Baylor College of Medicine to Biological E, a commercial vaccine manufacturer, for scale-up, production, testing, and licensure. JHK reports personal fees from SK Biosciences. ![]() Switzerland N Strub-Wourgaft (Drugs for Neglected Diseases Initiative, Geneva). India G Kang (Christian Medical College, Vellore). Saudi Arabia M Hassanain (King Saud University, Riyadh). UK S Gilbert (Oxford University, Oxford) H Larson, A Wilder-Smith (London School of Hygiene & Tropical Medicine, London). ![]() Jamaica J P Figueroa (University of the West Indies at Mona, Kingston). Turkey O Ergonul (Koc University Research Center for Infectious Diseases, Istanbul) M Gursel (Middle East Technical University, Ankara). Brazil C Batista (Médecins Sans Frontières, Rio de Janeiro). USA P Hotez, M E Bottazzi (co-chairs Baylor College of Medicine, Houston, TX) B Lall (assistant to co-chairs University of Houston College of Medicine, Houston, TX) T Sheahan (University of North Carolina, Chapel Hill, NC) S Shoham (Johns Hopkins University School of Medicine, Baltimore, MD) P Yadav (Center for Global Development, Washington, DC). South Korea J H Kim (International Vaccine Institute, Seoul). An important question is: how will these Operation Warp Speed vaccines be used for COVID-19 prevention in global health settings? We address some key questions that arise in the transition from US to global vaccine prevention efforts and from ethical and logistical issues to those that are relevant to global vaccine security, justice, equity, and diplomacy. ![]() Depending on safety and efficacy, vaccines can become available through mechanisms for emergency use, expanded access with informed consent, or full licensure. The US programme known as Operation Warp Speed provided US$18 billion in funding for development of vaccines that were intended for US populations. Several global efforts are underway to develop COVID-19 vaccines, and interim analyses from phase 3 clinical testing have been announced by nine organisations: Pfizer, the Gamaleya Research Institute of Epidemiology and Microbiology, Moderna, AstraZeneca, Sinopharm Group, Sinovac Biotech, Johnson & Johnson, Novavax, and CanSino Biologics. The Lancet Regional Health – Western Pacific.The Lancet Regional Health – Southeast Asia.The Lancet Gastroenterology & Hepatology.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |